ArticleBlood advances2024

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.

V Koneti Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.